Health Condition 1: H350- Background retinopathy and retinalvascular changes
Conditions
Interventions
Intervention1: Intravitreal injection - Bevacizumab (Avastin): 1.25 mg of bevacizumab marketed by the name of Avastin will be injected intravitreally following PRN regimen
First injection will be give
Sponsors
NIl
Eligibility
Inclusion criteria
Inclusion criteria: 1. Central subfield retinal thickness of at least 300um measured by OCT 2. Centre involving macular edema 3. Visual acuity between 6/9 to 6/60
Exclusion criteria
Exclusion criteria: 1. Previous treatment in terms of : - a) Focal/macular photocoagulation b) Previous intravitreal injection therapy - Last 3 months c) PRP in the last 6 months 2. Any medial opacity obscuring the fundus view 3. Intra ocular pressure >21mmHg or previous steroid responders 4. Cataract surgery and YAG capsulotomy in the last 3 months 5. PDRP patients requiring simultaneous pan-retinal photocoagulation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement and comparison of average threshold for macular sensitivity via microperimetry between the two treatment arms Timepoint: 0, 1, 6 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Measurement and comparison of VA (snellenâ??s 3 metre), CSRT (OCT), fixation characteristics (microperimetry) and number of injections given between the two treatment arms Timepoint: 0, 1, 6 month | — |
Countries
India
Contacts
Public ContactSameer Chaudhary
Aravind Eye Hospital, Madurai
Outcome results
None listed